Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems

References

• Sharma U, Singh S. Immunobiology of leishmaniasis. Indian J. Exp. Biol.47(6), 412–423 (2009).
   PubMed Web of Science ®Google Scholar
• Desjeux P. Leishmaniasis: current situation and new perspective. Comp. Immunol. Microbiol. Infect. Dis.27, 305–318 (2004).
   PubMed Web of Science ®Google Scholar
• Costa CH, Peters NC, Maruyama SR, de Brito EC, Santos IKF. Vaccines for the leishmaniases: proposals for a research agenda. PLoS Neg. Trop. Dis.5(3), e943 (2011).
   PubMed Web of Science ®Google Scholar
• Desjeux P. Human leishmaniases: epidemiology and public health aspects. World Health Stat.45, 267–275 (1992).
   PubMedGoogle Scholar
• Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg.95, 239–243 (2001).
   PubMed Web of Science ®Google Scholar
• Desjeux P. Leishmaniasis. Nat. Rev. Microbiol.2, 692 (2004).
   PubMedGoogle Scholar
• Desjeux P, Alvar J. Leishmania/HIV co-infection: epidemiology in Europe. Ann. Trop. Med. Parasitol.97(1), 3–15 (2003).
   PubMed Web of Science ®Google Scholar
• Alvar J. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev.21, 334–359 (2008).
   PubMed Web of Science ®Google Scholar
• Ezra N, Ochoa MT, Craft N. Human immunodeficiency virus and leishmaniasis. J. Glob. Infect. Dis.2(3), 248–257 (2010).
   PubMedGoogle Scholar
• Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet366(9496), 1561–1577 (2005).
   PubMed Web of Science ®Google Scholar
• Herwaldt BL. Leishmaniasis. Lancet354(9185), 1191–1199 (1999).
   PubMed Web of Science ®Google Scholar
• Reithinger R, Dujardin JC, Louzir H et al. Cutaneous leishmaniasis. Lancet7, 581–596 (2007).
   Google Scholar
• Bravo F, Sanchez MR. New and re-emerging cutaneous infectious diseases in Latin America and other geographic areas. Dermatol. Clin.21(4), 655–668 (2003).
   PubMedGoogle Scholar
• James WD, Berger TG et al.Andrews’ Diseases of the Skin: Clinical Dermatology. Saunders Elsevier, ON, Canada (2006).
   Google Scholar
• Ganguly S, Das NK, Barbhuiya JN, Chatterjee M. Post-kala-azar dermal leishmaniasis – an overview. Int. J. Dermatol.49(8), 921–931 (2010).
   PubMedGoogle Scholar
• Dereure J, El-Safi SH, Bucheton B et al. Visceral leishmaniasis in eastern Sudan: parasite identification in humans and dogs host–parasite relationships. Microbes Infect.5(12), 1103–1108 (2003).
   PubMed Web of Science ®Google Scholar
• Modabber F. Leishmaniasis vaccines: past, present and future. Int. J. Antimicrob. Agents36(1), S58–S61 (2010).
   Web of Science ®Google Scholar
• Okwor I, Uzonna JE. Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature. Immunotherapy1(5), 765–776 (2009).
   PubMed Web of Science ®Google Scholar
• Khamesipour A, Dowlati Y, Asilian A et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine23(28), 3642–3648 (2005).
   PubMed Web of Science ®Google Scholar
• Noazin S, Khamesipour A, Moulton LH et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine27(35), 4747–4753 (2009).
   PubMed Web of Science ®Google Scholar
• Bertholet S, Goto Y, Carter L et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine27(50), 7036–7045 (2009).
   PubMed Web of Science ®Google Scholar
• Scott P, Pearce E, Natovitz P, Sher A. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract. J. Immunol.139(9), 3118–3125 (1987).
   PubMedGoogle Scholar
• Ramos I, Alonso A, Marcen JM et al. Heterologous prime–boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine26(3), 333–344 (2008).
   PubMed Web of Science ®Google Scholar
• Dunning N. Leishmania vaccines: from leishmanization to the era of DNA technology. Biosci. Horizons2(1), 73–82 (2009).
   Google Scholar
• Daneshvar H, Molaei MM, Kamiabi H, Burchmore R, Hagan P, Stephen Phillips R. Gentamicin-attenuated Leishmania infantum: cellular immunity production and protection of dogs against experimental canine leishmaniasis. Parasite Immunol.32(11–12), 722–730 (2010).
   PubMedGoogle Scholar
• Nagill R, Kaur S. Vaccine candidates for leishmaniasis: a review. Int. Immunopharmacol.11(10), 1464–1488 (2011).
   PubMed Web of Science ®Google Scholar
• Mizbani A, Taheri T, Zahedifard F et al. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine28(1), 53–62 (2009).
   PubMed Web of Science ®Google Scholar
• Breton M, Tremblay MJ, Ouellette M et al. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect. Immun.73(10), 6372–6382 (2005).
   PubMed Web of Science ®Google Scholar
• Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Expert. Rev. Vaccines6(5), 673–684 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol.28, 445–489 (2010).
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity33, 451–463 (2010).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat. Immunol.12(6), 509–517 (2011).
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol.11, 373–384 (2010).
   PubMed Web of Science ®Google Scholar
• Demento SL, Siefert AL, Bandyopadhyay A, Sharp FA, Fahmy TM. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol.29(6), 294–306 (2011).
   PubMed Web of Science ®Google Scholar
• Miyaji EN, Carvalho E, Oliveira ML, Raw I, Ho PL. Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants. Braz. J. Med. Biol. Res.4(6), 500–513 (2011).
   Google Scholar
• Schenten D, Medzhitov R. The control of adaptive immune responses by the innate immune system. Adv. Immunol.109, 87–124 (2011).
   PubMed Web of Science ®Google Scholar
• Moresco EM, Lavine D, Beutler B. Toll-like receptors. Curr. Biol.21(13), 488–493 (2011).
   PubMed Web of Science ®Google Scholar
• Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol.9, 465–479 (2009).
   PubMed Web of Science ®Google Scholar
• Ting JP, Duncan JA, Lei Y. How the non inflammasome NLRs function in the innate immune system. Science327, 286–290 (2010).
   PubMed Web of Science ®Google Scholar
• Onoguchi K, Yoneyama M, Fujita T. Retinoic acid-inducible gene-I-like receptors. J. Interferon Cytokine Res.31(1), 27–31 (2011).
   PubMed Web of Science ®Google Scholar
• Gallego C, Golenbock D, Gomez MA, Saravia NG. Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis. Infect. Immun.79(7), 2871–2879 (2011).
   PubMed Web of Science ®Google Scholar
• Silva GK, Gutierrez FR, Guedes PM et al. Cutting edge: nucleotide-binding oligomerization domain 1-dependent responses account for murine resistance against Trypanosoma cruzi infection. J. Immunol.184(3), 1148–1152 (2010).
   PubMed Web of Science ®Google Scholar
• Sharp F, Ruane D, Claas B et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl Acad. Sci USA106, 870–875 (2009).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell124, 849–863 (2006).
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity33, 492–503 (2010).
   PubMed Web of Science ®Google Scholar
• Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity29, 319–324 (2008).
   PubMed Web of Science ®Google Scholar
• Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity33, 516–529 (2010).
   PubMed Web of Science ®Google Scholar
• McKee AS, Macleod MK, Kappler JW, Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol.8, 37 (2010).
   PubMed Web of Science ®Google Scholar
• Pajtasz-Piasecka E, Indrová M. Dendritic cell-based vaccines for the therapy of experimental tumors. Immunotherapy2(2), 257–268 (2010).
   PubMed Web of Science ®Google Scholar
• Gerlach C, van Heijst JW, Schumacher TN. The descent of memory T cells. Ann. NY Acad. Sci.1217, 139–153 (2011).
   PubMedGoogle Scholar
• Bhowmick S, Ali N. Recent developments in leishmaniasis vaccine delivery systems. Expert. Opin. Drug Deliv.5(7), 789–803 (2008).
   PubMed Web of Science ®Google Scholar
• Mutiso M, Macharia JC, Gicheru MM. A review of adjuvants for Leishmania vaccine candidates. J. Biomed. Res.24(1), 16–25 (2010).
   PubMedGoogle Scholar
• Afonso LC, Scharton TM, Vieira LQ et al. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science263(5144), 235–237 (1994).
   PubMed Web of Science ®Google Scholar
• Gicheru MM, Olobo JO, Anjili CO et al. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect. Immun.69(1), 245–251 (2001).
   PubMed Web of Science ®Google Scholar
• Skeiky YA, Coler RN, Brannon M et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine20(27–28), 3292–3303 (2002).
   PubMed Web of Science ®Google Scholar
• Badaro R, Lobo I, Nakatani M et al. Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: a case report. Braz. J. Infect. Dis.5(4), 223–232 (2001).
   PubMedGoogle Scholar
• Badaró R, Nascimento C, Carvalho JS et al. Recombinant human granulocyte–macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J. Infect. Dis.170(2), 413–418 (1994).
   PubMed Web of Science ®Google Scholar
• Milstien JB, Gibson JJ. Quality control of BCG vaccine by WHO: a review of factors that may influences vaccine effectiveness and safety. WHO Bull. OMS68, 93–108 (1990).
   PubMed Web of Science ®Google Scholar
• Simila S, Liedes E, Kinnunen P. Sternal abscess as a complication of BCG reactivation. Tubercle69, 67–69 (1988).
   PubMedGoogle Scholar
• Oliveira GA, Wetzel K, Calvo-Calle JM et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a Phase I trial. Infect. Immun.73(6), 3587–3597 (2005).
   PubMed Web of Science ®Google Scholar
• Collins WE, Barnwell JW, Sullivan JS et al. Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees. Am. J. Trop. Med. Hyg.74(2), 215–221 (2006).
   PubMed Web of Science ®Google Scholar
• Rafati S, Nakhaee A, Taheri T et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine23(28), 3716–3725 (2005).
   PubMed Web of Science ®Google Scholar
• Scheibner V. Adverse effects of adjuvants in vaccines. Exp. Mol. Pathol.8, 1–2 (2000).
   Google Scholar
• Gurunathan S, Prussin C, Sacks DL, Seder RA. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med.4(12), 1409–1415 (1998).
   PubMed Web of Science ®Google Scholar
• Kenney RT, Sacks DL, Sypek JP et al. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol.163(8), 4481–4488 (1999).
   PubMed Web of Science ®Google Scholar
• Misra A, Dube A, Srivastava B et al. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine19(25–26), 3485–3492 (2001).
   PubMed Web of Science ®Google Scholar
• Lindblad EB. Aluminium compounds for use in vaccines. Immunol. Cell Biol.82(5), 497–505 (2004).
   PubMed Web of Science ®Google Scholar
• Reed SG, Coler RN, Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Expert. Rev. Vaccines2(2), 239–252 (2003).
   PubMedGoogle Scholar
• Chakravarty J, Kumar S, Trivedi S et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine29(19), 3531–3537 (2011).
   PubMed Web of Science ®Google Scholar
• Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect. Immun.75(9), 4648–4654 (2007).
   PubMed Web of Science ®Google Scholar
• Verthelyi D, Klinman DM. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin. Immunol.109(1), 64–71 (2003).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv. Drug Deliv. Rev.61(3), 248–255 (2009).
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Safaiyan SH, Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol. Cancer10, 3 (2011).
   PubMed Web of Science ®Google Scholar
• Rafati S, Ghaemimanesh F, Zahedifard F. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, protein/protein and DNA/protein) against Leishmania major infection using signal peptidase type I in BALB/c mice. Vaccine24(16), 3290–3297 (2006).
   PubMedGoogle Scholar
• Flynn B, Wang V, Sacks DL et al. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs. Infect. Immun.73(8), 4948–4954 (2005).
   PubMed Web of Science ®Google Scholar
• Rhee EG, Mendez S, Shah JA et al. Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J. Exp. Med.195(12), 1565–1573 (2002).
   PubMed Web of Science ®Google Scholar
• Quintilio W, Kubrusly FS, Iourtov D et al.Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine27(31), 4219–4224 (2009).
   PubMedGoogle Scholar
• Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun.56(12), 3272–3279 (1988).
   PubMed Web of Science ®Google Scholar
• Handman E, Symons FM, Baldwin TM et al. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a Th1 type of immune response. Infect. Immun.63(11), 4261–4267 (1995).
   PubMed Web of Science ®Google Scholar
• Pandey R, Ahmad Z. Nanomedicine and experimental tuberculosis: facts, flaws, and future. Nanomedicine7(3), 259–272 (2011).
   PubMed Web of Science ®Google Scholar
• Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Deliv Rev.60, 915–928 (2008).
   PubMed Web of Science ®Google Scholar
• Van Rooijen N, Sanders A. The macrophage as target or obstacle in liposome-based targeting strategies. Int. J. Phar.162(1–2), 45–50 (1998).
   Google Scholar
• Burke B, Sumner S, Maitland N, Lewis CE. Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J. Leuk. Biol.72(3), 417–428 (2002).
   PubMed Web of Science ®Google Scholar
• Espuelas S. Treatment and prevention of leishmaniasis. Gaz. Méd. Bahia.79(3), 134–146 (2009).
   Google Scholar
• Kreuter J. Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacokinet.19, 253–256 (1994).
   PubMed Web of Science ®Google Scholar
• Prijic S, Sersa G. Magnetic nanoparticles as targeted delivery systems in oncology. Radiol. Oncol.45(1), 1–16 (2011).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines2(2), 269–283 (2003).
   PubMedGoogle Scholar
• Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles. J. Biotech.113, 151–170 (2004).
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Eskandari M, Khamesipour A, Jaafari MR. Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis. Exp. Parasitol.129(2), 107–114 (2011).
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Eskandari M, Kharazizadeh M, Khamesipour A, Jaafari MR. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins. Trop. Biomed.27(3), 639–650 (2010).
   PubMed Web of Science ®Google Scholar
• Santos LE, Colhone MC, Daghastanli KR, Stabeli RG, Silva-Jardim I, Ciancaglini P. Lipid microspheres loaded with antigenic membrane proteins of the Leishmania amazonensis as a potential biotechnology application. J. Colloid. Interface Sci.340(1), 112–118 (2009).
   PubMedGoogle Scholar
• Doroud D, Zahedifard F, Vatanara A et al. C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice. PLoS Negl. Trop. Dis.5(7), e1236 (2011).
   PubMed Web of Science ®Google Scholar
• Doroud D, Zahedifard F, Vatanara A et al. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J. Control. Release153(2), 154–162 (2011).
   PubMed Web of Science ®Google Scholar
• Doroud D, Zahedifard F, Vatanara A, Najafabadi AR, Rafati S. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice. Parasite Immunol.33(6), 335–348 (2011).
   PubMed Web of Science ®Google Scholar
• Doroud D, Vatanara A, Zahedifard F et al. Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J. Pharm. Pharm. Sci.13(3), 320–335 (2010).
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC. Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm. Res.18(1), 1–8 (2001).
   PubMed Web of Science ®Google Scholar
• França A, Aggarwal P, Barsov EV, Kozlov SV, Dobrovolskaia MA, González-Fernández Á. Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine (Lond.)6(7), 1175–1188 (2011).
   PubMed Web of Science ®Google Scholar
• Kelly C, Jefferies C, Cryan SA. Targeted Liposomal drug delivery to monocytes and macrophages. J. Drug Del. (2011) (In Press).
   PubMedGoogle Scholar
• Aderem A, Underhill D. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol.17, 593–623 (1999).
   PubMed Web of Science ®Google Scholar
• Champion JA, Mitragotri S. Role of target geometry in phagocytosis. PNAS103(13), 4930–4934 (2006).
   PubMed Web of Science ®Google Scholar
• Aderem A. How to eat something bigger than your head. Cell110, 5–8 (2002).
   PubMedGoogle Scholar
• Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm.71, 161–172 (2009).
   PubMed Web of Science ®Google Scholar
• Brewer JM, Tetley L, Richmond J, Liew FY, Alexander J. Cellular immunology and immune regulation: lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J. Immunol.161, 4000–4007 (1998).
   PubMed Web of Science ®Google Scholar
• Lincopan N, Espindolab NM, Vazb AJ, da Costa MH, Faquim-Mauroc E, Carmona-Ribeiro AM. Novel immunoadjuvants based on cationic lipid: preparation, characterization and activity in vivo. Vaccine27(42), 5760–5771 (2009).
   PubMedGoogle Scholar
• Fifis T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: therapeutic and protective properties of nanovaccines against tumors. J. Immunol.173, 3148–3173 (2004).
   PubMed Web of Science ®Google Scholar
• Brewer JM, Pollock KGJ, Tetley L, Russell DG. Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles. J. Immunol.173, 6143–6150 (2004).
   PubMed Web of Science ®Google Scholar
• Chen HC, Sun B, Tran KK, Shen H. Effects of particle size on Toll-like receptor 9-mediated cytokine profiles. Biomaterials32, 1731–1737 (2011).
   PubMedGoogle Scholar
• Mayer A, Vadon M, Rinner B, Novak A, Wintersteiger R,Fröhlich E. The role of nanoparticle size in hemocompatibility. Toxicology258(2–3), 139–147 (2009).
   PubMed Web of Science ®Google Scholar
• Göppert TM, Müller RH. Plasma protein adsorption of Tween 80- and poloxamer 188-stabilized solid lipid nanoparticles. J. Drug Target.11(4), 225–231 (2003).
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mader K. Solid lipid nanoparticles production, characterization and applications. Adv. Drug Del. Rev.47, 165–196 (2001).
   PubMed Web of Science ®Google Scholar
• del Pozo-Rodríguez A, Delgado D, Solinis MA, Gascon AR, Pedraz JL. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int. J. Pharm.339, 261–268 (2007).
   PubMed Web of Science ®Google Scholar
• Seeballuck F, Lawless E, Ashford MB, O’Driscoll CM. Stimulation of triglyceriderich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using caco-2 cells and a cannulated rat intestinal lymphatic model. Pharm. Res.21, 2320–2326 (2004).
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, Ott G, O’Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl Acad. Sci.97(8), 11–16 (2000).
   Google Scholar
• Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J. Control. Release76, 59–71 (2001).
   PubMed Web of Science ®Google Scholar
• Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD, Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol. Membr. Biol.23(5), 385–395 (2006).
   PubMed Web of Science ®Google Scholar
• Yan W, Chen W, Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol. Immunol.44(15), 3672–3681 (2007).
   PubMed Web of Science ®Google Scholar
• Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials31(26), 6867–6875 (2010).
   PubMed Web of Science ®Google Scholar
• Wasungu L, Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control. Release116(2), 255–264 (2006).
   PubMed Web of Science ®Google Scholar
• Nobs L, Buchegger F, Gurny R, Allémann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Pharm. Sci.93(8), 1980–1992 (2004).
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Takagi H, Nakayama T et al. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages. Parasite Immunol.29(5), 229–239 (2007).
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Yamakami K, Gomi T et al. Protection against Leishmania major infection by oligomannose-coated liposomes. Bioorg. Med. Chem.11(7), 1191–1195 (2003).
   PubMed Web of Science ®Google Scholar
• McConville MJ, Bacic A, Mitchell GF, Handman E. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor. Proc. Natl Acad. Sci. USA84(24), 8941–8945 (1987).
   PubMed Web of Science ®Google Scholar
• Danesh-Bahreini MA, Shokri J, Samiei A, Kamali-Sarvestani E, Barzegar-Jalali M, Mohammadi-Samani S. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. Int. J. Nanomed.6, 835–842 (2011).
   PubMed Web of Science ®Google Scholar
• Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC. Vaccination with recombinant Leishmania donovani γ-glutamylcysteine synthetase fusion protein protects against L. donovani infection. J. Parasitol.96(5), 929–936 (2010).
   PubMedGoogle Scholar
• Bhowmick S, Mazumdar T, Sinha R, Ali N. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani. J. Control. Release141, 199–207 (2010).
   PubMed Web of Science ®Google Scholar
• Ravindran R, Bhowmick S, Das A, Ali N. Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis. BMC Microbiol.10, 181 (2010).
   PubMed Web of Science ®Google Scholar
• Badiee A, Jaafari MR, Khamesipour A et al. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition. Colloids Surf. B. Biointerfaces74(1), 37–44 (2009).
   PubMed Web of Science ®Google Scholar
• Badiee A, Jaafari MR, Khamesipour A et al. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63). Experimental Parasitol.121(4), 362–369 (2009).
   PubMed Web of Science ®Google Scholar
• Badiee A, Jaafari MR, Samiei A, Soroush D, Khamesipour A. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin. Vacc. Immunol.15(4), 668–674 (2008).
   PubMed Web of Science ®Google Scholar
• Bhowmick S, Ravindran R, Ali N. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect. Immun.76(3), 1003–1015 (2008).
   PubMed Web of Science ®Google Scholar
• Gomez CS. In-vivo delivery of DNA vaccines using metallo-lipid nanoparticles. ETD Collection for University of Texas, El Paso, TX, USA (2008).
   Google Scholar
• Jaafari MR, Ghafarian A, Farrokh-Gisour A et al. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine24(29–30), 5708–5717 (2006).
   PubMed Web of Science ®Google Scholar
• Mazumder S, Ravindran R, Banerjee A, Ali N. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice. Vaccine25(52), 8771–8781 (2007).
   PubMed Web of Science ®Google Scholar
• Badiee A, Jaafari MR, Khamesipour A. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Exp. Parasitol.115(2), 127–134 (2007).
   PubMed Web of Science ®Google Scholar
• Sharma SK, Dube A, Nadeem A et al. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. Vaccine24(11), 1800–1810 (2006).
   PubMed Web of Science ®Google Scholar
• Santos FR, Ferraz DB, Daghastanli KR, Ramalho-Pinto FJ, Ciancaglini P. Mimetic membrane system to carry multiple antigenic proteins from Leishmania amazonensis. J. Membr. Biol.210(3), 173–181 (2006).
   PubMed Web of Science ®Google Scholar
• Mazumdar T, Anam K, Ali N. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine22(9–10), 1162–1171 (2004).
   PubMed Web of Science ®Google Scholar
• Afrin F, Rajesh R, Anam K, Gopinath M, Pal S, Ali N. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect. Immun.70(12), 6697–6706 (2002).
   PubMed Web of Science ®Google Scholar
• Afrin F, Anam K, Ali N. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes. J. Parasitol.86(4), 730–735 (2000).
   PubMed Web of Science ®Google Scholar
• Afrin F, Ali N. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect. Immun.65(6), 2371–2377 (1997).
   PubMed Web of Science ®Google Scholar
• Lezama-Dávila CM. Vaccination of different strains of mice against cutaneous leishmaniosis: usefulness of membrane antigens encapsulated into liposomes by intraperitoneal and subcutaneous administration. Arch. Med. Res.28(1), 47–53 (1997).
   PubMedGoogle Scholar
• Yang DM, Rogers MV, Liew FY. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major. Immunology72(1), 3–9 (1991).
   PubMedGoogle Scholar
• Kahl LP, Scott CA, Lelchuk R, Gregoriadis G, Liew FY. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization. J. Immunol.142(12), 4441–4449 (1989).
   PubMed Web of Science ®Google Scholar
• Russell DG, Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J. Immunol.140(4), 1274–1279 (1988).
   PubMed Web of Science ®Google Scholar
• Pal I, Ramsey JD. The role of the lymphatic system in vaccine trafficking and immune response. Adv. Drug Deliv. Rev.63(10-11), 909–922 (2011).
   PubMed Web of Science ®Google Scholar
• Christensen D, Korsholm KS, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines10(4), 513–521 (2011).
   PubMed Web of Science ®Google Scholar
• Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Expert. Opin. Drug. Del.8, 505–519 (2011).
   PubMed Web of Science ®Google Scholar
• Jesorka A, Orwar O. Liposomes: technologies and analytical applications. Ann. Rev. Anal. Chem.1, 801–832 (2008).
   PubMed Web of Science ®Google Scholar
• Bhowmick S, Mazumdar T, Ali N. Vaccination route that induces transforming growth factor β production fails to elicit protective immunity against Leishmania donovani infection. Infect. Immun.77, 1514–1523 (2004).
   Google Scholar
• Rafati S, Zahedifard F, Nazgouee F. Prime–boost vaccination using cysteine proteinases types I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine24, 2169–2175 (2006).
   PubMed Web of Science ®Google Scholar
• Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol.38, 1404–1413 (2008).
   PubMed Web of Science ®Google Scholar
• Rafati S, Salmanian AH, Taheri T, Vafa M, Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine19, 3369–3375 (2001).
   PubMed Web of Science ®Google Scholar